Price T Rowe Associates Inc Liquidia Corp Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Liquidia Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 27,377 shares of LQDA stock, worth $420,236. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,377
Previous 24,623
11.18%
Holding current value
$420,236
Previous $290,000
39.31%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding LQDA
# of Institutions
189Shares Held
45.2MCall Options Held
473KPut Options Held
464K-
Black Rock Inc. New York, NY4.24MShares$65.1 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.99MShares$61.3 Million0.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$53.2 Million0.0% of portfolio
-
Findell Capital Management LLC New York, NY2.89MShares$44.4 Million20.5% of portfolio
-
Opaleye Management Inc. Boston, MA2.26MShares$34.7 Million9.17% of portfolio
About Liquidia Corp
- Ticker LQDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,362,300
- Market Cap $988M
- Description
- Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...